Phantom test procedures for a new neuro-oncological amino acid PET tracer: [
Amino acid
Glioma
Neuro-oncology
Quantitative evaluation
Standardization
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
29 Aug 2024
29 Aug 2024
Historique:
received:
17
05
2024
accepted:
21
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
aheadofprint
Résumé
Amino acid positron emission tomography (PET) examinations using anti-1-amino-3-[ Background (BG) activity as well as hot sphere and target-to-background ratios (TBRs) of [ The amounts of activity in the hot spheres and BG were 1.1 and 5.5 kBq/mL, respectively, and the TBR was 5.0 at the start of acquisition. The %contrast We estimated phantom activity and TBR based on brain activity in a Japanese clinical trial and established new phantom test procedures for [
Identifiants
pubmed: 39207631
doi: 10.1007/s12149-024-01973-x
pii: 10.1007/s12149-024-01973-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP23K14875
Informations de copyright
© 2024. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.
Références
Kubota K. From tumor biology to clinical pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med. 2001;15(6):471–86.
doi: 10.1007/BF02988499
pubmed: 11831394
Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48(9):1468–81.
doi: 10.2967/jnumed.106.037689
pubmed: 17704239
Castello A, Castellani M, Florimonte L, Ciccariello G, Mansi L, Lopci E. PET radiotracers in glioma: a review of clinical indications and evidence. Clin Trans Imag. 2022;10(5):535–51.
doi: 10.1007/s40336-022-00523-7
Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imag. 2013;40(4):615–35.
doi: 10.1007/s00259-012-2295-5
Heiss WD, Raab P, Lanfermann H. Multimodality assessment of brain tumors and tumor recurrence. J Nucl Med. 2011;52(10):1585–600.
doi: 10.2967/jnumed.110.084210
pubmed: 21840931
Najjar AM, Johnson JM, Schellingerhout D. The emerging role of amino acid PET in neuro-oncology. Bioengineering (Basel). 2018;5(4):104.
Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishiwata K, et al. Usefulness of L-[methyl-
doi: 10.3171/jns.2005.103.3.0498
pubmed: 16235683
Uda T, Tsuyuguchi N, Terakawa Y, Takami T, Ohata K. Evaluation of the accumulation of 11C-methionine with standardized uptake value in the normal brain. J Nucl Med. 2010;51(2):219–22.
doi: 10.2967/jnumed.109.068783
pubmed: 20080891
Wagatsuma K, Ikemoto K, Inaji M, Kamitaka Y, Hara S, Tamura K, et al. Impact of [
Tsuyuguchi N, Terakawa Y, Uda T, Nakajo K, Kanemura Y. Diagnosis of brain tumors using amino acid transport PET imaging with 18F-fluciclovine: a comparative study with L-methyl-11C-methionine PET imaging. Asia Ocean J Nucl Med Biol. 2017;5(2):85–94.
pubmed: 28660218
pmcid: 5482923
Wakabayashi T, Iuchi T, Tsuyuguchi N, Nishikawa R, Arakawa Y, Sasayama T, et al. Diagnostic performance and safety of positron emission tomography using 18F-fluciclovine in patients with clinically suspected high- or low-grade gliomas: a multicenter phase IIb trial. Asia Ocean J Nucl Med Biol. 2017;5(1):10–21.
pubmed: 28840134
pmcid: 5221680
Michaud L, Beattie BJ, Akhurst T, Dunphy M, Zanzonico P, Finn R, et al.
doi: 10.1007/s00259-019-04433-1
Kondo A, Ishii H, Aoki S, Suzuki M, Nagasawa H, Kubota K, et al. Phase IIa clinical study of [
doi: 10.1007/s12149-016-1102-y
pubmed: 27418267
Wakabayashi T, Hirose Y, Miyake K, Arakawa Y, Kagawa N, Nariai T, et al. Determining the extent of tumor resection at surgical planning with 18F-fluciclovine PET/CT in patients with suspected glioma: multicenter phase III trials. Ann Nucl Med. 2021;35(12):1279–92.
doi: 10.1007/s12149-021-01670-z
pubmed: 34406623
Japanese Society of Nuclear Medicine. Standard PET imaging protocols and phantom test procedures and criteria: executive summary.: Japanese Society of Nuclear Medicine; 2017 [Available from: http://jsnm.sakura.ne.jp/wp_jsnm/wp-content/themes/theme_jsnm/doc/StandardPETProtocolPhantom20170201.pdf . Accessed 30 Apr. 2024.
Yamaguchi S, Wagatsuma K, Miwa K, Ishii K, Inoue K, Fukushi M. Bayesian penalized-likelihood reconstruction algorithm suppresses edge artifacts in PET reconstruction based on point-spread-function. Phys Med. 2018;47:73–9.
doi: 10.1016/j.ejmp.2018.02.013
pubmed: 29609821
Asano Y, Inoue Y, Ikeda Y, Kikuchi K, Hara T, Taguchi C, et al. Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[
doi: 10.1007/s12149-011-0477-z
pubmed: 21409348
Nihon Medi-Physics Co., Ltd.. Information on AXUMIN Injection: Pharmaceuticals and Medical Devices Agency; 2021 [Available from: https://www.pmda.go.jp/drugs/2021/P20210330001/530359000_30300AMX00246_B100_1.pdf . (Japanese) Accessed 30 Apr. 2024.
Wagatsuma K, Miwa K, Sakata M, Oda K, Ono H, Kameyama M, et al. Comparison between new-generation SiPM-based and conventional PMT-based TOF-PET/CT. Phys Med. 2017;42:203–10.
doi: 10.1016/j.ejmp.2017.09.124
pubmed: 29173917
Miwa K, Umeda T, Murata T, Wagatsuma K, Miyaji N, Terauchi T, et al. Evaluation of scatter limitation correction: a new method of correcting photopenic artifacts caused by patient motion during whole-body PET/CT imaging. Nucl Med Commun. 2016;37(2):147–54.
doi: 10.1097/MNM.0000000000000403
pubmed: 26440565
Wagatsuma K, Oda K, Sakata M, Inaji M, Miwa K, Sasaki M, et al. Validation of scatter limitation correction to eliminate scatter correction error in oxygen-15 gas-inhalation positron emission tomography images. Nucl Med Commun. 2018;39(10):936–44.
doi: 10.1097/MNM.0000000000000882
pubmed: 29985832
Wagatsuma K, Miwa K, Akamatsu G, Yamao T, Kamitaka Y, Sakurai M, et al. Toward standardization of tau PET imaging corresponding to various tau PET tracers: a multicenter phantom study. Ann Nucl Med. 2023;37(9):494–503.
doi: 10.1007/s12149-023-01847-8
pubmed: 37243882
Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. JointEANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [
Wagatsuma K, Miwa K, Kamitaka Y, Koike E, Yamao T, Yoshii T, et al. Determination of optimal regularization factor in Bayesian penalized likelihood reconstruction of brain PET images using [
doi: 10.1002/mp.15593
pubmed: 35246870
Akamatsu G, Shimada N, Matsumoto K, Daisaki H, Suzuki K, Watabe H, et al. New standards for phantom image quality and SUV harmonization range for multicenter oncology PET studies. Ann Nucl Med. 2022;36(2):144–61.
doi: 10.1007/s12149-021-01709-1
pubmed: 35029817
Kaalep A, Sera T, Rijnsdorp S, Yaqub M, Talsma A, Lodge MA, et al. Feasibility of state of the art PET/CT systems performance harmonisation. Eur J Nucl Med Mol Imaging. 2018;45(8):1344–61.
doi: 10.1007/s00259-018-3977-4
pubmed: 29500480
pmcid: 5993859
Karlberg A, Pedersen LK, Vindstad BE, Skjulsvik AJ, Johansen H, Solheim O, et al. Diagnostic accuracy of anti-3-[
doi: 10.1007/s00259-023-06437-4
Akamatsu G, Ikari Y, Nishida H, Nishio T, Ohnishi A, Maebatake A, et al. Influence of statistical fluctuation on reproducibility and accuracy of SUVmax and SUVpeak: a phantom study. J Nucl Med Technol. 2015;43(3):222–6.
doi: 10.2967/jnmt.115.161745
pubmed: 26271802
Karlberg A, Berntsen EM, Johansen H, Myrthue M, Skjulsvik AJ, Reinertsen I, et al. Multimodal 18F-fluciclovine PET/MRI and ultrasound-guided neurosurgery of an anaplastic oligodendroglioma. World Neurosurg. 2017;108(989):e1–8.
Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [
doi: 10.1158/1078-0432.CCR-04-0262
pubmed: 15534088
Murata T, Miwa K, Miyaji N, Wagatsuma K, Hasegawa T, Oda K, et al. Evaluation of spatial dependence of point spread function-based PET reconstruction using a traceable point-like 22Na source. EJNMMI Phys. 2016;3(1):26.
doi: 10.1186/s40658-016-0162-3
pubmed: 27783373
pmcid: 5080272
Rahmim A, Qi J, Sossi V. Resolution modeling in PET imaging: theory, practice, benefits, and pitfalls. Med Phys. 2013;40(6): 064301.
doi: 10.1118/1.4800806
pubmed: 23718620
pmcid: 3663852
van der Vos CS, Koopman D, Rijnsdorp S, Arends AJ, Boellaard R, van Dalen JA, et al. Quantification, improvement, and harmonization of small lesion detection with state-of-the-art PET. Eur J Nucl Med Mol Imag. 2017;44(Suppl 1):4–16.
Girard A, Francois M, Chaboub N, Le Reste PJ, Devillers A, Saint-Jalmes H, et al. Impact of point-spread function reconstruction on dynamic and static 18F-DOPA PET/CT quantitative parameters in glioma. Quant Imag Med Surg. 2022;12(2):1397–404.
doi: 10.21037/qims-21-742
Prieto E, Marti-Climent JM, Moran V, Sancho L, Barbes B, Arbizu J, et al. Brain PET imaging optimization with time of flight and point spread function modelling. Phys Med. 2015;31(8):948–55.
doi: 10.1016/j.ejmp.2015.07.001
pubmed: 26249138
Miwa K, Wagatsuma K, Nemoto R, Masubuchi M, Kamitaka Y, Yamao T, et al. Detection of sub-centimeter lesions using digital TOF-PET/CT system combined with Bayesian penalized likelihood reconstruction algorithm. Ann Nucl Med. 2020;34(10):762–71.
doi: 10.1007/s12149-020-01500-8
pubmed: 32623569
Miwa K, Yoshii T, Wagatsuma K, Nezu S, Kamitaka Y, Yamao T, et al. Impact of gamma factor in the penalty function of Bayesian penalized likelihood reconstruction (Q.Clear) to achieve high-resolution PET images. EJNMMI Phys. 2023;10(1):4.
Yoshii T, Miwa K, Yamaguchi M, Shimada K, Wagatsuma K, Yamao T, et al. Optimization of a Bayesian penalized likelihood algorithm (Q.Clear) for
Wagatsuma K, Sakata M, Miwa K, Hamano Y, Kawakami H, Kamitaka Y, et al. Phantom and clinical evaluation of the Bayesian penalised likelihood reconstruction algorithm Q.Clear without PSF correction in amyloid PET images. EJNMMI Phys. 2024;11(1):37.
Yamagishi S, Miwa K, Kamitaki S, Anraku K, Sato S, Yamao T, et al. Performance characteristics of a new-generation digital bismuth germanium oxide PET/CT system, omni legend 32, according to NEMA NU 2–2018 standards. J Nucl Med. 2023;64(12):1990–7.
doi: 10.2967/jnumed.123.266140
pubmed: 37857503